Articles

Poll

Podcasts

Slideshows

Videos

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

The Q2 recap for gastroenterology spotlights top coverage from DDW, expert perspective on the importance of multidisciplinary care, and other new research.

Q2 2025 Recap: Gastroenterology News and Updates

The month in review spotlights perspectives on collaborative GI care, updates in C diff, and new research about disorders of gut brain interaction.

Gastroenterology Month in Review: June 2025

The analysis of Rome Foundation Global Epidemiology Study data identified 4 dietary pattern clusters linked to variations in the global prevalence and severity of IBS.

Regional Dietary Patterns Tied to Global Prevalence, Severity of IBS

Despite adequate adherence to a gluten-free diet and declining TTG IgA values, 43% of the pediatric celiac disease patients met Rome IV diagnostic criteria for DGBI.

DGBI Common in Children with Adequately Managed Celiac Disease, Study Finds

Guan describes the potential value of using wearable devices to enhance IBS management by tracking sleep and exercise.

Leveraging Wearable Devices for IBS Self Management, with Michelle Guan, MD

Jeemin Kwon, MD, describes the role GI symptom-related anxiety plays in shaping dietary patterns and altering the gut microbiome in patients with IBS.

GI Symptom Related-Anxiety Drives Restrictive Eating in IBS

EBX-102-02 was well tolerated and led to clinically meaningful improvements across multiple symptom domains in patients with IBS-C.

EBX-102-02, A Full-Spectrum Microbiome Drug, Shows Promise for IBS-C in Phase 2a Trial

This month in review spotlights HCPLive’s coverage of gastroenterology pipeline news, a feature about gastroparesis and migraine, and recent GI research.

Gastroenterology Month in Review: January 2025

The approval of Amneal Pharmaceuticals’ generic version of rifaximin 550 mg oral tablets is tentative due to the product’s involvement in litigation.

FDA Grants Tentative Approval to Generic Version of Rifaximin for IBS-D

This year in review spotlights top GI FDA news from 2024 and new clinical guidance from the American Gastroenterological Association.

Gastroenterology Year in Review: 2024

On the HCPLive irritable bowel syndrome page, resources on the topics of medical news and expert insight into IBS can be found. Content includes articles, interviews, videos, podcasts, and breaking news on IBS, IBD, and more.

Irritable Bowel Syndrome